when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BRISTOL · news · pharmadog

← back to BRISTOL

News mentioning BRISTOL

236 stories

Aug 3, 26Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideafiercebiotech

Aug 2, 26AstraZeneca, Bristol Myers in talks about merger — reportendpoints

Jul 31, 26Trump administration tries again to institute rebates in 340Bbiopharma dive

Jul 31, 26Moderna maintains 10% growth target despite Phase 3 norovirus missbiospace

Jul 31, 26Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsbiopharma dive

Jul 31, 26Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPOendpoints

Jul 30, 26Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapybiospace

Jul 30, 26Replimune melanoma drug wins support of FDA panelbiopharma dive

Jul 30, 26Replimune’s twice-rejected melanoma drug prevails in FDA adcommfiercebiotech

Jul 30, 26Chutes & Ladders—Legend CEO departs without successor in placefiercebiotech

Jul 30, 26J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6Bbiopharma dive

Jul 30, 26BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysbiospace

Jul 30, 26Takeda, Regeneron, Sanofi and Bristol Myers trim pipelinesendpoints

Jul 30, 26BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearfiercebiotech

Jul 30, 26Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatfiercebiotech

Jul 30, 26Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsfiercebiotech

Jul 30, 26Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storebiospace

Jul 30, 26Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policystat

Jul 30, 26J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutfiercebiotech

Jul 29, 26MapLight CEO on what investors missed in the biotech’s schizophrenia databiopharma dive

Jul 29, 26Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationfiercebiotech

Jul 28, 26FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcommbiospace

Jul 27, 26MapLight dives despite positive data for schizophrenia drugbiopharma dive

Jul 27, 26MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readoutbiospace

Jul 27, 26MapLight shares sink on mixed phase 2 schizophrenia readoutfiercebiotech

Jul 27, 26InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testfiercebiotech

Jul 27, 26Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlebiospace

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 25, 26Anthropic’s life science plans; Novartis CEO on China deals; and moreendpoints

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

← prevpage 5 of 8next →